Related Experiment Video
Updated: Jan 23, 2026

Using Zebrafish Larvae to Study the Pathological Consequences of Hemorrhagic Stroke
Published on: June 5, 2019
Antiarrhythmic Effect of Sacubitril-Valsartan: Cause or Consequence of Clinical Improvement?
António Valentim Gonçalves1, Tiago Pereira-da-Silva2, Ana Galrinho3
1Department of Cardiology, Hospital de Santa Marta, Centro Hospitalar de Lisboa Central, 1169-024 Lisbon, Portugal. antonio.a.goncalves.14@gmail.com.
Insights
Sacubitril/Valsartan (LCZ696) therapy significantly reduced QTc interval, QRS duration, and mechanical dispersion in heart failure patients. This suggests a potential mechanism for reducing ventricular arrhythmias.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Sacubitril/Valsartan (LCZ696) reduced sudden cardiac death in the PARADIGM-HF trial.
- The mechanism by which LCZ696 reduces ventricular arrhythmias is unclear.
Purpose of the Study:
- To compare electrocardiographic (ECG) parameters and mechanical dispersion index, assessed by left ventricular (LV) global longitudinal strain (GLS), before and after LCZ696 therapy.
Main Methods:
- Prospective evaluation of chronic Heart Failure (HF) patients with LV ejection fraction ≤40% receiving LCZ696.
- ECG and transthoracic echocardiographic data were collected before and at six months of LCZ696 therapy.
- Mechanical dispersion index was defined as the standard deviation from 16 time intervals of LV GLS.
Main Results:
- QTc interval (451.9 vs. 426.0 ms, p < 0.001), QRS duration (125.1 vs. 120.8 ms, p = 0.033), and mechanical dispersion index (88.4 vs. 78.1 ms, p = 0.036) were significantly reduced at six months.
- 35 out of 42 patients completed the six-month follow-up.
Conclusions:
- LCZ696 therapy is associated with a reduction in QTc interval, QRS duration, and mechanical dispersion index.
- These findings suggest a potential mechanism for LCZ696's antiarrhythmic effects in heart failure patients.
Abstract:
Sacubitril/Valsartan (LCZ696) reduced sudden cardiac death in the PARADIGM-HF trial. However, the mechanism by which LCZ696 reduces ventricular arrhythmias remains unclear. The aim of this study was to compare electrocardiographic (ECG) parameters and mechanical dispersion index, assessed by left ventricular (LV) global longitudinal strain (GLS), before and after LCZ696 therapy. We prospectively evaluated chronic Heart Failure (HF) patients with LV ejection fraction ≤40%, despite optimal medical and device therapy, in which LCZ696 therapy was started, while no additional HF treatment was expected to change. ECG and transthoracic echocardiographic data were gathered in the week before starting LCZ696 and at six months of therapy. A semiautomated analysis of LV GLS was performed and mechanical dispersion index was defined as the standard deviation from 16 time intervals corresponding to each LV segment. Of the 42 patients, 35 completed the six month follow-up, since two patients died and five discontinued treatment for adverse events. QTc interval (451.9 vs. 426.0 ms, p < 0.001), QRS duration (125.1 vs. 120.8 ms, p = 0.033) and mechanical dispersion index (88.4 vs. 78.1 ms, p = 0.036) were significantly reduced at six months. LCZ696 therapy is associated with a reduction in QTc interval, QRS duration and mechanical dispersion index as assessed by LV GLS.
Related Concept Videos
Timing and Consequences on Behavior
Humans, however, can respond to delayed reinforcers. We often make decisions between immediate small rewards and delayed larger rewards. This ability to delay gratification is a significant...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Nursing Clinical Information System
A Nursing Clinical Information System (NCIS) is a specialized type of healthcare information system tailored to meet the unique needs of nursing practice. It incorporates the principles of nursing informatics to streamline information management and improve the quality of care delivery.
Critical attributes of NCIS include:

